Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs

Table 2 Characteristics of patients in included trials

Trail (Study ID)	Country	Study type	The number of patients, n			Age, year (mean/mean ± SD)		Male sex, n(%)
Trail (Study ID)	Country	Study type	MSC	Ctrl	Total	MSC	Ctr	Male sex, n(%)
Monsel et al. [22]	France	Phase 2b RCT	21	24	45	64 ± 10.4	63.2 ± 11.4	37(82.2%)
Bellingan et al. [21]	UK	Phase 2a trial RCT	20	10	30	51 ± 14	59 ± 18	19 (63.3%)
Lanzoni et al. [20]	USA	Phase 1/2a trial RCT	12	12	24	58.6 ± 15.9	58.8 ± 11.6	13 (54.2%)
Matthay et al. [19]	USA	Phase 2a trial RCT	40	20	60	55 ± 17	55 ± 20	33 (55%)
Zheng et al. [18]	China	phase 1 trial RCT	6	6	12	66.7 ± 20.4	69.8 ± 9.1	11(91.7%)

Trail (Study ID)	PaO₂/FiO₂, mmHg (mean ± SD)/ median (IQR)		SOFA score (mean ± SD)		Primary ARDS Cause	Lung Injury Score (mean ± SD)
Trail (Study ID)	MSC	Ctrl	MSC	Ctrl	Primary ARDS Cause	MSC	Ctrl
Monsel et al. [22]	156.2 ± 68.2	171.2 ± 72.9	5.5 ± 2.7	5.9 ± 2.7	COVID-19	3.0 ± 0.7	2.8 ± 0.5
Bellingan et al. [21]	173 ± 56.4	128 ± 35.1	10.9 ± 2.2^a	12.2 ± 4.2^a	Pneumonia	NR	NR
Lanzoni et al. [20]	124 (68–164)^b	108.5 (68.5–165.5)^b	NR	NR	COVID-19	NR	NR
Matthay et al. [19]	135.8 ± 32.3	143.3 ± 39	8.1 ± 3.3	6.9 ± 2.7	Pneumonia	3.1 ± 0.4	3.0 ± 0.5
Zheng et al. [18]	122.4 ± 42	103.5 ± 32.2	NR	NR	Pneumonia	NR	NR

^aModified SOFA, For SOFA scoring, all patients were assigned a nervous system domain score + 4 = Glasgow Coma Score (GCS) < 6
^bPaO₂/FiO₂: median (IQR)
RCT Randomized Controlled Trial, MSC Mesenchymal stromal cell group, Ctrl Control group, NR not reported

ISSN: 1757-6512